NasdaqCM:HTBX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient’s immune system against cancer through T-cell activation and expansion.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Heat Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HTBX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

30.1%

HTBX

-0.7%

US Biotechs

2.0%

US Market


1 Year Return

31.4%

HTBX

23.4%

US Biotechs

7.1%

US Market

Return vs Industry: HTBX exceeded the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: HTBX exceeded the US Market which returned 7.1% over the past year.


Shareholder returns

HTBXIndustryMarket
7 Day30.1%-0.7%2.0%
30 Day67.4%3.3%6.0%
90 Day192.7%14.4%-0.05%
1 Year31.4%31.4%24.6%23.4%9.5%7.1%
3 Year-86.2%-86.2%34.6%30.1%30.7%22.1%
5 Year-98.5%-98.5%-3.1%-8.9%55.6%38.0%

Price Volatility Vs. Market

How volatile is Heat Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Heat Biologics undervalued compared to its fair value and its price relative to the market?

2.79x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HTBX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HTBX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HTBX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: HTBX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HTBX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HTBX is good value based on its PB Ratio (2.8x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is Heat Biologics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-16.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HTBX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HTBX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HTBX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HTBX's revenue (53.7% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: HTBX's revenue (53.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HTBX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Heat Biologics performed over the past 5 years?

-3.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HTBX is currently unprofitable.

Growing Profit Margin: HTBX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HTBX is unprofitable, and losses have increased over the past 5 years at a rate of -3.3% per year.

Accelerating Growth: Unable to compare HTBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HTBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: HTBX has a negative Return on Equity (-78.92%), as it is currently unprofitable.


Next Steps

Financial Health

How is Heat Biologics's financial position?


Financial Position Analysis

Short Term Liabilities: HTBX's short term assets ($27.1M) exceed its short term liabilities ($6.9M).

Long Term Liabilities: HTBX's short term assets ($27.1M) exceed its long term liabilities ($4.4M).


Debt to Equity History and Analysis

Debt Level: HTBX is debt free.

Reducing Debt: HTBX has no debt compared to 5 years ago when its debt to equity ratio was 15.1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HTBX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HTBX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 6.8% each year.


Next Steps

Dividend

What is Heat Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HTBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HTBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HTBX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HTBX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HTBX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Jeff Wolf (56yo)

11.92yrs

Tenure

US$2,405,032

Compensation

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D., is the Chief Executive Officer and President of Heat Biologics, Inc. since August 2008 and served as its Treasurer and Secretary. Mr. Wolf Co-Founded Pelica ...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD2.41M) is above average for companies of similar size in the US market ($USD589.04K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Wolf
Founder11.92yrsUS$2.41m4.66% $3.8m
William Ostrander
VP of Finance & Secretary0.67yrUS$266.85kno data
Jeff Hutchins
Chief Scientific Officer & COO2.92yrsUS$932.14k0.17% $138.3k
Justin Stebbing
Chief Medical Advisor and Member of Scientific & Clinical Advisory Boardno datano datano data
George Peoples
Chief Medical Advisor3.08yrsno datano data

3.0yrs

Average Tenure

56yo

Average Age

Experienced Management: HTBX's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Wolf
Founder11.92yrsUS$2.41m4.66% $3.8m
Justin Stebbing
Chief Medical Advisor and Member of Scientific & Clinical Advisory Boardno datano datano data
John K. Prendergast
Independent Lead Director3.67yrsUS$539.00k0.83% $676.2k
John Monahan
Independent Director10.5yrsUS$201.90k0.00061% $498.9
Llew Keltner
Member of Scientific & Clinical Advisory Boardno datano datano data
Roger Cohen
Member of Scientific & Clinical Advisory Boardno datano datano data
Gary Acton
Member of Scientific & Clinical Advisory Boardno datano datano data
Robert Negrin
Member of Scientific Advisory Board2.58yrsno datano data
Edward Smith
Independent Director9.5yrsUS$212.90k0.0012% $965.1
Robert Levy
Member of Scientific Advisory Board2.58yrsno datano data

6.6yrs

Average Tenure

62.5yo

Average Age

Experienced Board: HTBX's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 148.5%.


Top Shareholders

Company Information

Heat Biologics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Heat Biologics, Inc.
  • Ticker: HTBX
  • Exchange: NasdaqCM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$81.791m
  • Shares outstanding: 84.67m
  • Website: https://www.heatbio.com

Number of Employees


Location

  • Heat Biologics, Inc.
  • 627 Davis Drive
  • Suite 400
  • Morrisville
  • North Carolina
  • 27560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HTBXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 2013
1HB1DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2013

Biography

Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient’s immune system against cancer through T-cell activation and expansion. The company’s T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer; and HS-130, which is in phase I clinical trials for the treatment of advanced solid tumors. The company’s preclinical stage products include PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling, as well as develops COVID-19 vaccine program and diagnostic test. The company was founded in 2008 and is headquartered in Morrisville, North Carolina. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/28 04:30
End of Day Share Price2020/05/27 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.